Provera

Endometrial Hyperplasia, Endometriosis, Chronic Pain + 18 more

Treatment

7 FDA approvals

20 Active Studies for Provera

What is Provera

Medroxyprogesterone acetate

The Generic name of this drug

Treatment Summary

Medroxyprogesterone acetate (MPA) is a hormonal medication that is designed to stay in the body longer than other progesterone derivatives. It is used to treat several conditions, including amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, menopausal symptoms, and vulvar and vaginal atrophy. MPA is also used as a contraceptive and in palliative care for endometrial and renal cancers. It was approved by the FDA in 1959.

Medroxyprogesterone Acetate

is the brand name

image of different drug pills on a surface

Provera Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Medroxyprogesterone Acetate

Medroxyprogesterone acetate

1959

139

Approved as Treatment by the FDA

Medroxyprogesterone acetate, also known as Medroxyprogesterone Acetate, is approved by the FDA for 7 uses such as Vasomotor Symptoms Associated With Menopause and Vulvo Vaginal Atrophy .

Vasomotor Symptoms Associated With Menopause

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Vulvo Vaginal Atrophy

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Postmenopausal Osteoporosis

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Hot flashes

Used to treat Menopause in combination with Conjugated estrogens

Hot Flashes

Used to treat Vasomotor Symptoms Associated With Menopause in combination with Conjugated estrogens

Osteoporosis, Postmenopausal

Used to treat Postmenopausal Osteoporosis in combination with Conjugated estrogens

Atrophic

Used to treat Vulvo Vaginal Atrophy in combination with Conjugated estrogens

Effectiveness

How Provera Affects Patients

Medroxyprogesterone acetate (MPA) is used to treat a variety of conditions. It works by blocking the hormones that cause the growth of certain tissues, including endometrial tissue. MPA is available in several different forms and can last anywhere from 40-60 hours to a full week depending on the form taken. People may take doses between 5mg to 1000mg depending on their condition. However, long-term use of MPA can lead to weakened bones and lower peak bone mass, which can eventually lead to osteoporosis and fractures.

How Provera works in the body

Medroxyprogesterone acetate (MPA) stops ovulation and thins the endometrium, making it harder for a pregnancy to occur. It does this by reducing the activity of estrogen receptors in the endometrium and blocking a key hormone in the ovulation process. It may also help to kill certain types of cancer cells, as well as block some of the receptors in the brain that control relaxation.

When to interrupt dosage

The endorsed dose of Provera is contingent upon the acknowledged affliction, including Hormonal Contraception, Amenorrhea and Postmenopausal Osteoporosis. The measure additionally varies as indicated by the technique of delivery (e.g. Tablet - Oral or Intramuscular) featured in the table beneath.

Condition

Dosage

Administration

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Chronic Pain

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Amenorrhea

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

conjugated estrogen

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

hypoestrogenism

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Birth Control

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometriosis

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Endometrial Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Fracture

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Osteoporosis, Postmenopausal

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Estrogen Replacement Therapy

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hot Flashes

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Uterine hemorrhage

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Atrophic

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Hormonal Contraception

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Kidney Neoplasms

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Pharmaceutical Preparations

, 2.5 mg, 10.0 mg, 5.0 mg, 150.0 mg/mL, 400.0 mg/mL, 1.5 mg, 100.0 mg, 1040.0 mg/mL, 500.0 mg, 250.0 mg, 200.0 mg, 400.0 mg, 250.0 mg/mL, 50.0 mg/mL

Oral, Tablet - Oral, , Tablet, Injection, suspension, Injection, suspension - Intramuscular, Intramuscular, Tablet, sugar coated - Oral, Tablet, sugar coated, Suspension - Intramuscular, Suspension, Kit; Tablet - Oral, Kit; Tablet, Subcutaneous, Injection, suspension - Subcutaneous, Kit, Injection, suspension, extended release, Injection, suspension, extended release - Intramuscular, Injection - Intramuscular, Injection, Kit - Oral

Warnings

Provera has fifteen contraindications, so should not be combined with the conditions described in the ensuing table.

Provera Contraindications

Condition

Risk Level

Notes

Thromboembolism

Do Not Combine

Breast

Do Not Combine

Thrombophlebitis

Do Not Combine

Neoplasms, Hormone-Dependent

Do Not Combine

Breast

Do Not Combine

Breast Cancer

Do Not Combine

Stroke

Do Not Combine

Vascular Diseases

Do Not Combine

Thromboembolism

Do Not Combine

Liver Disease

Do Not Combine

estrogen-dependent neoplasia

Do Not Combine

suspected pregnancy

Do Not Combine

Disease

Do Not Combine

undiagnosed abnormal genital bleeding

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Medroxyprogesterone Acetate may interact with Pulse Frequency

There are 20 known major drug interactions with Provera.

Common Provera Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Medroxyprogesterone acetate.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Medroxyprogesterone acetate.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Medroxyprogesterone acetate.

Alpelisib

Major

The metabolism of Alpelisib can be increased when combined with Medroxyprogesterone acetate.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Medroxyprogesterone acetate.

Provera Toxicity & Overdose Risk

The lowest toxic dose of medroxyprogesterone acetate (MPA) in rats and mice is greater than 6400mg/kg and 16g/kg, respectively. Symptoms of an overdose include nausea, vomiting, breast tenderness, dizziness, abdominal pain, drowsiness, fatigue, and irregular bleeding. Treatment for an overdose includes stopping MPA and providing symptomatic relief. If a patient has been given too much MPA in a depo injection, they should seek medical help or contact a poison control center right away.

image of a doctor in a lab doing drug, clinical research

Provera Novel Uses: Which Conditions Have a Clinical Trial Featuring Provera?

406 active clinical trials are currently being conducted to assess the potential of Provera for the treatment of Osteoporosis, Amenorrhea and Hormonal Contraception.

Condition

Clinical Trials

Trial Phases

Endometriosis

27 Actively Recruiting

Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Endometrial Neoplasms

0 Actively Recruiting

Fracture

0 Actively Recruiting

Osteoporosis, Postmenopausal

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Birth Control

22 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2

Estrogen Replacement Therapy

0 Actively Recruiting

Hormonal Contraception

0 Actively Recruiting

Endometriosis

2 Actively Recruiting

Phase 4, Not Applicable

Hot Flashes

4 Actively Recruiting

Not Applicable, Phase 2, Phase 1

Kidney Neoplasms

35 Actively Recruiting

Phase 1, Phase 3, Phase 2, Not Applicable

conjugated estrogen

0 Actively Recruiting

Hot flashes

19 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3

hypoestrogenism

1 Actively Recruiting

Phase 4

Atrophic

4 Actively Recruiting

Phase 4, Not Applicable

Amenorrhea

0 Actively Recruiting

Pharmaceutical Preparations

0 Actively Recruiting

Endometrial Hyperplasia

4 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Provera Reviews: What are patients saying about Provera?

5

Patient Review

9/10/2019

Provera for Absence of Menstrual Periods in Woman Who Has Had Them

I was really irregular with my periods, to the point where my partner and I thought I might be pregnant. When we went to the doctor, they prescribed Provera. It's only been five days but it's already made a world of difference. If you're struggling with irregular periods, please talk to your doctor about this medication.

5

Patient Review

1/6/2022

Provera for Abnormal Uterine Bleeding caused by Imbalance of Hormones

I have large fibroids and was on birth control for 14 years. The doctor took me off, and I had just had a period. 2 days later I started bleeding again. Took provera, and now I'm not bleeding but my body feels different like depressed etc.

5

Patient Review

11/24/2019

Provera for Post-Menopausal Symptoms

I've been taking this medication alongside estrogen to combat serious post-menopausal symptoms. It's effective, but I have noticed that I've become more impatient and quick to anger. Has anyone else experienced this?

5

Patient Review

6/27/2022

Provera for Absence of Menstrual Periods in Woman Who Has Had Them

Took as directed for ten days. Heavier than normal period but no other negative side effects that I could tell.

5

Patient Review

5/12/2022

Provera for Prevention of Abnormal Growth in Cells of Uterine Lining

This treatment has been absolutely life-changing for me. I no longer feel exhausted or nauseous, and I've even lost weight because of the increased energy levels.

2.3

Patient Review

9/9/2022

Provera for Abnormal Uterine Bleeding caused by Imbalance of Hormones

I have pcos and have been bleeding for 8 months. I know that sounds crazy, but besides the bleeding I was fine. My gynecologist put me on provera for 7 days to stop the bleeding worst anxiety of my life I could barley function then I hade the most dark and depressing thoughts then when I came off the pills my bleeding was worse to the point of potential needing a blood transfusion. I absolutely do not recommend this medication.

1

Patient Review

6/14/2022

Provera for Absence of Menstrual Periods in Woman Who Has Had Them

I took this medication to help with my pcos and missed periods. Unfortunately, it caused me to have a very heavy period with lots of clots several weeks later. I wouldn't recommend this medication to anyone because it was too much for my body to handle.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about provera

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Provera used for?

"Provera is a prescription medication used to treat the symptoms of heavy menstrual bleeding, irregular menstrual bleeding, or no menstrual bleeding at all. Provera can be used alone or with other medications. Provera belongs to a class of drugs called antineoplastics, hormones, and progestins."

Answered by AI

How many days after Provera should I get my period?

"The period should occur 3 to 7 days after starting Provera. If you do not have a period after finishing a course of Provera, consult a doctor to check for pregnancy. Take the tablet as soon as you remember and continue taking the tablets at normal intervals."

Answered by AI

What does Provera do to the lining of the uterus?

"Medroxyprogesterone may cause lighter periods if taken every day, as it can thin the uterine lining. However, since it is only taken for around 10 days at a time, it typically does not stop periods entirely."

Answered by AI

Why do doctors prescribe Provera?

"PROVERA, used in combination with an estrogen-containing medicine, can help relieve symptoms of menopause in women who still have a uterus. This is called hormone replacement therapy (HRT). PROVERA can help protect the lining of the uterus while estrogens relieve menopausal symptoms."

Answered by AI

Clinical Trials for Provera

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of AltaSciences, Inc in Cypress, United States.

SBS-147 Safety Study

18 - 55
All Sexes
Cypress, CA

This study is part of the HEAL Initiative supported by the NIH. The purpose of this study is to learn how safe the study drug, SBS-147, is and how people's bodies respond to and process it. Researchers will also look for any side effects that may occur when taking SBS-147. Some participants will receive SBS-147, and others will receive a placebo, which looks the same but does not contain any medicine. This helps researchers fairly compare results. The study includes two parts: Single-Dose Group, where Participants receive SBS-147 or placebo one time. Multiple-Dose Group, where Participants receive SBS-147 or placebo once or twice daily for 7 days.

Phase 1
Waitlist Available

AltaSciences, Inc

Jeff Reich, MD

Sparian Biosciences, Inc

Image of Inova Schar Cancer Institute in Fairfax, United States.

Acupuncture for Prostate Cancer

18+
Male
Fairfax, VA

Prostate cancer is the most common cancer among men in the United States. Many men with prostate cancer are treated with hormone therapy, also called androgen deprivation therapy (ADT). While this treatment is effective, it often causes bothersome side effects such as hot flashes, poor sleep, fatigue, and other physical and emotional symptoms. There is currently no standard treatment to help manage these side effects in men. Acupuncture is a non-drug treatment that has been shown to help reduce hot flashes and related symptoms in women receiving hormone therapy for breast cancer. However, much less is known about whether acupuncture is helpful for men receiving hormone therapy for prostate cancer. This study will test whether an acupuncture program, combined with usual lifestyle education, is feasible and acceptable for men undergoing ADT. The study will also explore whether acupuncture may help reduce hot flashes and improve related symptoms. A total of 24 men with prostate cancer receiving ADT will be randomly assigned to one of two groups: one group will begin acupuncture right away, and the other group will begin acupuncture after a delay, with regular check-ins during the waiting period. All participants will receive standard lifestyle education. Participants will be followed for about five months and will be asked to complete daily hot flash diaries, questionnaires about their symptoms and quality of life, and wear a Fitbit to track sleep. The results of this pilot study will help determine whether a larger study should be conducted to better understand the role of acupuncture in managing hormone therapy side effects in men with prostate cancer.

Waitlist Available
Has No Placebo

Inova Schar Cancer Institute

Jeanny Aragon-Ching, MD

Have you considered Provera clinical trials?

We made a collection of clinical trials featuring Provera, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Have you considered Provera clinical trials?

We made a collection of clinical trials featuring Provera, we think they might fit your search criteria.
Go to Trials
Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Have you considered Provera clinical trials?

We made a collection of clinical trials featuring Provera, we think they might fit your search criteria.
Go to Trials